Research, Science and Treatments


BREAKING NEWS: Data Released from Anetumab Ravtansine Study

Last week, at the World Conference on Lung Cancer, Dr. Raffit Hassan presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.
“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants […]



Pharmaceutical Company Completes Enrollment for Phase 1B Trial for Mesothelioma

If you attended our International Symposium on Malignant Mesothelioma in March of this year, you may recall the buzz of excitement that coursed throughout the scientific sessions. This buzz sparked excitement throughout the entire mesothelioma community, as we discussed advances in science, the needs of those affected by this disease, and the work being done […]